EGFR and non-small cell lung carcinoma: Afatinib is a second-generation tyrosine kinase inhibitor and irreversible ErbB-family blocker that is used for the first-line treatment of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) [1].